Amgen: A collaborative and personalized approach to early and moderate PsA


Valkenburg

Satellite Symposium
03 June 2020 18:15 - 19:45

Three lectures plus interactive roundtable of the Faculty, including Q&A sessions exploring the evidence and sharing expert perspectives on: 

  1. The importance of collaborative and multidisciplinary approach in identifying patients with early and moderate Psoriatic Arthritis (PsA), in recognizing their clinical features, including different dermatological manifestations, for differential diagnosis of PsA and understanding of disease burden and unmet needs. 

  1. The value of personalized medicine to target different phenotypic manifestations of PsA and how recent and emerging data could be used to optimize treatment decision making in clinical practice. 

  1. Considerations around the value of PDE-4 inhibition as a treatment option for patients with moderate PsA and other core manifestations of the disease. 

 

 

Oligoarticular PsA in clinical practice: understanding the unmet needs in an underserved patient population 

PsA patients with oligoarticular manifestations represent a relevant population in clinical practice. Real world data in these patients demonstrate the presence of additional disease domains and comorbid conditions. The unmet needs in oligoarticular PsA will be discussed to increase recognition of these patients and to improve their management in clinical practice. Research agenda to address data gaps will be debated. 

 

The value of identifying dermatological manifestation in differential diagnosis of PsA 

Description of different dermatologic manifestations in PsA patients, their heterogenicity in localization but also in severity and course. What is their value in differential diagnosis of PsA? What is the are the challenges in identifying and treating these manifestations?  

 

A tailored approach to the treatment of patients with moderate PsA: optimizing treatment decisions 

Clinical trials in PsA patients focus predominantly on polyarticular disease. How can emerging data be used to optimize identification of patients with early, moderate disease? Treatment choices should tailor therapies to the phenotype of disease, considering all PsA disease manifestations as well as the safety profile of treatment options 


 


Presentations

Title Time Add to calendar
Opening statement & Oligoarticular PsA in clinical practice: understanding the unmet needs in an underserved patient population
03 June 2020 18:15 - 18:32 Add to calendar
The value of identifying dermatological manifestation in differential diagnosis of PsA
03 June 2020 18:32 - 18:49 Add to calendar
A tailored approach to the treatment of patients with moderate PsA: optimizing treatment decisions
03 June 2020 18:49 - 19:06 Add to calendar
Wrap-up and Closure by the Chair
(Speaker to be announced)
03 June 2020 19:06 - 19:12 Add to calendar